Diagnostic Financings Are Robust, Fueled by COVID-19 and Precision Medicine
Private investors poured more than $8 billion into diagnostics companies between January 2020 and September 30, 2021, envisioning myriad opportunities for innovative COVID-19 testing technologies and precision medicine tests that help optimize individual treatment regimens.
Diagnostic Financings Are Robust, Fueled by COVID-19 and Precision Medicine
Published in MedTechStrategist
Author: Wendy Diller
Abstract:
Private investors poured more than $8 billion into diagnostics companies between January 2020 and September 30, 2021, envisioning myriad opportunities for innovative COVID-19 testing technologies and precision medicine tests that help optimize individual treatment regimens.
News
Outcome Capital Launches the First Dedicated Ophthalmology Practice to Address the World’s Leading Cause of Disability
Appoints Paul Ryb Managing Director to Lead Firm’s Expansion BOSTON – July 8, 2025 – Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Paul Ryb has been appointed Managing Director and will lead the firm’s dedicated ophthalmology practice, providing strategic guidance, transactional support, and advisory […]
Read MoreResources
Outcome Capital Life Science Market Pulse, May 2025
Outcome Capital Life Science Market Pulse May 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
